demonstrated that, in conjunction with Amyloid Precursor Protein/Death Receptor 6 Inhibitor 12, the nanocatalytic enhancer (VF/S/A@CaP) significantly curtailed the migration of osimertinib-resistant NSCLC, hinting at a potential nanocatalysis-based methodology for treating severe osimertinib-resistant NSCLC (66). The gene discussed is APP; the disease is non-small cell lung carcinoma.